Skip to main content
Signal8

Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program

$JAGXPress releaseJun 22, 2026, 9:00 AM ETRead the release

Jaguar Health's board has initiated a process to explore strategic alternatives, including potential mergers or acquisitions, to maximize stockholder value in alignment with its anticipated NDA filing for crofelemer. Third-party market research estimates the market for the rare intestinal failure indication at $1.1 billion in 2026, growing to $1.5 billion by 2033.

Key figures

Drug Name
crofelemer
Mvid market 2026
$1.1 billion
Mvid market 2033
$1.5 billion
Parenteral support reduction
up to 37%

AI analysis

Red flags2 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    JAGX: Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program — AI Analysis | Signal8